Bardoxolone methyl

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Bardoxolone methyl
DrugBank Accession Number
DB05983
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 505.699
Monoisotopic: 505.319208869
Chemical Formula
C32H43NO4
Synonyms
  • Bardoxolone methyl
External IDs
  • NSC-713200
  • RTA 402
  • RTA-402

Pharmacology

Indication

Investigated for use/treatment in lymphoma (unspecified), multiple myeloma, and solid tumors.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

RTA 402 inhibits the activity of nuclear factor kappa-B (NF-kB) activated by tumor necrosis factor (TNF) and other inflammatory agents in a variety of cancer cells. It is a novel targeted cancer therapy with a unique mechanism of action. It exploits fundamental physiological differences between cancerous and noncancerous cells by modulating oxidative stress response pathways. As a result, the drug is toxic to cancer cells but induces protective antioxidant and anti-inflammatory responses in normal cells.

TargetActionsOrganism
UNF-kappa-B inhibitor alphaNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as cyclohexenones. These are compounds containing a cylohexenone moiety, which is a six-membered aliphatic ring that carries a ketone and has one endocyclic double bond.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Cyclohexenones
Alternative Parents
Methyl esters / Nitriles / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Aliphatic homopolycyclic compound / Carbonitrile / Carboxylic acid derivative / Carboxylic acid ester / Cyclohexenone / Hydrocarbon derivative / Methyl ester / Monocarboxylic acid or derivatives / Nitrile / Organic nitrogen compound
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
CEG1Q6OGU1
CAS number
218600-53-4
InChI Key
WPTTVJLTNAWYAO-KPOXMGGZSA-N
InChI
InChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1
IUPAC Name
methyl (4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicene-4a-carboxylate
SMILES
COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2

References

General References
Not Available
ChemSpider
355161
BindingDB
217379
ChEMBL
CHEMBL1762621
ZINC
ZINC000003982151
Wikipedia
Bardoxolone_methyl

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentDiabetic Kidney Disease (DKD)1
3RecruitingTreatmentAlport Syndrome / Autosomal Dominant Polycystic Kidney Disease (ADPKD) / Chronic Kidney Disease (CKD)1
3RecruitingTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD)1
3TerminatedTreatmentConnective Tissue Disease-Associated Pulmonary Arterial Hypertension1
3TerminatedTreatmentPulmonary Hypertension (PH)1
3TerminatedTreatmentRenal Insufficiency,Chronic / Type 2 Diabetes Mellitus1
2Active Not RecruitingTreatmentChronic Kidney Disease (CKD)1
2CompletedTreatmentAcute interstitial pneumonitis / Cryptogenic Organizing Pneumonia / Desquamative Interstitial Pneumonia / Idiopathic Interstitial Pneumonias / Idiopathic Lymphoid Interstitial Pneumonia / Idiopathic Pleuroparenchymal Fibroelastosis / Idiopathic Pulmonary Fibrosis (IPF) / Interstitial Lung Diseases (ILD) / Pulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH) / Respiratory Bronchiolitis Associated Interstitial Lung Disease / Sarcoidosis1
2CompletedTreatmentAutosomal Dominant Polycystic Kidney Disease (ADPKD) / CKD Associated With Type 1 Diabetes / Focal Segmental Glomerulosclerosis (FSGS) / IgA Nephropathy (IgAN)1
2CompletedTreatmentChronic Kidney Disease (CKD) / Diabetic Nephropathy / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00294 mg/mLALOGPS
logP5.29ALOGPS
logP6.55ChemAxon
logS-5.2ALOGPS
pKa (Strongest Basic)-5.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area84.23 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity144.36 m3·mol-1ChemAxon
Polarizability58.23 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Inhibits the activity of dimeric NF-kappa-B/REL complexes by trapping REL dimers in the cytoplasm through masking of their nuclear localization signals. On cellular stimulation by immune and proinf...
Gene Name
NFKBIA
Uniprot ID
P25963
Uniprot Name
NF-kappa-B inhibitor alpha
Molecular Weight
35608.65 Da

Drug created on November 18, 2007 18:29 / Updated on February 21, 2021 18:51